Literature DB >> 18295203

TGF-beta1-induced cardiac myofibroblasts are nonproliferating functional cells carrying DNA damages.

Victor V Petrov1, Jos F van Pelt, Joris R Vermeesch, Viktor J Van Duppen, Katrien Vekemans, Robert H Fagard, Paul J Lijnen.   

Abstract

TGF-beta1 induces differentiation and total inhibition of cardiac MyoFb cell division and DNA synthesis. These effects of TGF-beta1 are irreversible. Inhibition of MyoFb proliferation is accompanied with the expression of Smad1, Mad1, p15Ink4B and total inhibition of telomerase activity. Surprisingly, TGF-beta1-activated MyoFbs are growth-arrested not only at G1-phase but also at S-phase of the cell cycle. Staining with TUNEL indicates that these cells carry DNA damages. However, the absolute majority of MyoFbs are non-apoptotic cells as established with two apoptosis-specific methods, flow cytometry and caspase-dependent cleavage of cytokeratin 18. Expression in MyoFbs of proliferative cell nuclear antigen even in the absence of serum confirms that these MyoFbs perform repair of DNA damages. These results suggest that TGF-beta1-activated MyoFbs can be growth-arrested by two checkpoints, the G1/S checkpoint, which prevents cells from entering S-phase and the intra-S checkpoint, which is activated by encountering DNA damage during the S phase or by unrepaired damage that escapes the G1/S checkpoint. Despite carrying of the DNA damages TGF-beta1-activated MyoFbs are highly functional cells producing lysyl oxidase and contracting the collagen matrix.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18295203     DOI: 10.1016/j.yexcr.2008.01.014

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  9 in total

Review 1.  Effects of altered plasminogen activator inhibitor-1 expression on cardiovascular disease.

Authors:  Victoria A Ploplis
Journal:  Curr Drug Targets       Date:  2011-11       Impact factor: 3.465

2.  DIM attenuates TGF-β1-induced myofibroblast differentiation in neonatal rat cardiac fibroblasts.

Authors:  Jin Li; Wenbin Zhang; Rong Jiao; Zheng Yang; Yuan Yuan; Qingqing Wu; Zhefu Hu; Shizhao Xiang; Qizhu Tang
Journal:  Int J Clin Exp Pathol       Date:  2015-05-01

3.  Mineralocorticoid receptor antagonism attenuates vascular apoptosis and injury via rescuing protein kinase B activation.

Authors:  Yongzhong Wei; Adam T Whaley-Connell; Javad Habibi; Jenna Rehmer; Nathan Rehmer; Kamlesh Patel; Melvin Hayden; Vincent DeMarco; Carlos M Ferrario; Jamal A Ibdah; James R Sowers
Journal:  Hypertension       Date:  2008-12-29       Impact factor: 10.190

Review 4.  Purpose and regulation of stem cells: a systems-biology view from the Caenorhabditis elegans germ line.

Authors:  Olivier Cinquin
Journal:  J Pathol       Date:  2009-01       Impact factor: 7.996

5.  Syndecan-3 and Notch cooperate in regulating adult myogenesis.

Authors:  Addolorata Pisconti; D D W Cornelison; Hugo C Olguín; Tiffany L Antwine; Bradley B Olwin
Journal:  J Cell Biol       Date:  2010-08-09       Impact factor: 10.539

6.  Pyridoxamine improves survival and limits cardiac dysfunction after MI.

Authors:  Dorien Deluyker; Vesselina Ferferieva; Ronald B Driesen; Maxim Verboven; Ivo Lambrichts; Virginie Bito
Journal:  Sci Rep       Date:  2017-11-22       Impact factor: 4.379

Review 7.  Mesenchymal Stem Cell Migration and Tissue Repair.

Authors:  Xiaorong Fu; Ge Liu; Alexander Halim; Yang Ju; Qing Luo; And Guanbin Song
Journal:  Cells       Date:  2019-07-28       Impact factor: 6.600

8.  Reversible and irreversible differentiation of cardiac fibroblasts.

Authors:  Ronald B Driesen; Chandan K Nagaraju; Joëlle Abi-Char; Tamara Coenen; Paul J Lijnen; Robert H Fagard; Karin R Sipido; Victor V Petrov
Journal:  Cardiovasc Res       Date:  2013-12-23       Impact factor: 10.787

9.  Telomere dysfunction promotes transdifferentiation of human fibroblasts into myofibroblasts.

Authors:  Neetu Razdan; Themistoklis Vasilopoulos; Utz Herbig
Journal:  Aging Cell       Date:  2018-09-22       Impact factor: 9.304

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.